A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

September 23, 2020

Study Completion Date

September 23, 2020

Conditions

OverweightObesity

Interventions

DRUG

Semaglutide

Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss